期刊
JOURNAL OF DIABETES AND ITS COMPLICATIONS
卷 29, 期 2, 页码 196-202出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2014.11.012
关键词
lschemic heart disease; Insulin secretagogue; Retrospective cohort study; Type 2 diabetes; Atrial fibrillation
资金
- Canadian Diabetes Association [OG-2-09-2693-SS]
- Blanch/Wirtanen/Alberta Diabetes Foundation/Alberta Diabetes Institute Studentship for Diabetes Research
- Alliance for Canadian Health Outcomes Research in Diabetes (ACHORD) Studentship - Canadian Institutes for Health Research [OGT-88588]
- Alberta Innovates Health Solutions
- Alberta Diabetes Institute
- Alliance for Canadian Health Outcomes Research in Diabetes (ACHORD) Strategic Training Program in Diabetic Research
- Izaak Walton Killam Memorial Scholarship
- Canadian Diabetes Association Doctoral Studentship
- Alberta Innovates [201201154] Funding Source: researchfish
Aim: To evaluate the association between insulin secretagogues and adverse cardiovascular sequelae in type 2 diabetes patients hospitalized for ischemic heart disease (IHD). Methods: Administrative health records from Alberta, Canada between 1998 and 2010 were used to identify 2,254 gliclazide, 3,289 glyburide and 740 repaglinide users prior to an IHD-related hospitalization. Multivariable Cox regression models were used to compare the 30-day risk of a composite outcome of all-cause mortality or new onset of atrial fibrillation, stroke, heart failure or myocardial infarction according to insulin secretagogue use. Results: Mean (SD) age was 76.1 (6.9) years, and 60.7% were men. The composite outcome occurred in 322 (30.2%) gliclazide users, 455 (28.1%) glyburide users and 81(23.4%) repaglinide users within 30 days of IHD hospitalization. There were no differences in risk for glyburide use (adjusted hazard ratio [aHR] 0.91; 95% confidence interval [CI] 0.78-1.05) or repaglinide use (aHR 0.80; 95% CI 0.63-1.03) compared to gliclazide. Similar results were observed in analyses for each element of the composite outcome. Conclusions: In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据